Abstract 4400
Background
A strong scientific and public interest exists in the sustainability of pharmaceutical research and development and particularly the issue of anticancer drug prices. Despite of the number of publications, articles seem often opinion-based. To facilitate an evidence-based discourse, we reviewed the literature and produced an inventory of policy proposals. We then analyze the available quantitative evidence.
Methods
Due to the broad nature of the research question, a scoping review was performed. We combined multiple search strategies to get a systematic overview of the current body of literature.
Results
In total, we screened 4775 articles and categorized 23 proposals. 22 of 85 included articles used quantitative models. Overall, the quantitative evidence was inconclusive to deduct real world effects and evidence- based recommendations. We however identified promising solutions for further investigation: Royalty payments, prizes and rewards, two-part-pricing, price transparency, increased translational public research, and public clinical trials. At ESMO, we will present this list of promising solutions, their degree of disruptiveness and their empirical evidence. Furthermore, we will share feedback on selected solutions from a survey among European experts in the field of oncology and health regulation. Finally, we will discuss techniques of evidence based solutions facing high complexity and the need of additional data for choosing policy options.
Conclusions
Despite of the urgency of the matte of drug prices, we must realize that system consequences need careful considerations as implications for access and finances can be substantial. We advise testing promising solutions with experiments, dynamic simulations, and policy pilots.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3664 - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract